Literature DB >> 27620888

Effect of sialidase fusion protein (DAS 181) on human metapneumovirus infection of Hep-2 cells.

Sutthiwan Thammawat1,2, Tania A Sadlon1, Penelope Adamson1, David L Gordon1.   

Abstract

METHODS: Hep-2 cells were preincubated with DAS181 or control DAS185 (a mutated sialidase) prior to inoculation with human metapneumovirus strains. Infectivity was assessed by a cell-based ELISA quantitating human metapneumovirus matrix protein. The effect of DAS181 on binding of recombinant G attachment protein was also determined.
RESULTS: DAS181 blocked infection of human metapneumovirus strains A2, B1, and B2 at low concentrations. No effect of DAS185 was observed. Binding of MPV G protein to Hep-2 cells was also markedly inhibited by preincubation of cells with DAS181.
CONCLUSIONS: These results suggest that human metapneumovirus may utilize sialic acids as an entry cofactor. DAS181 may thus represent a new therapeutic agent useful for the treatment of human metapneumovirus.

Entities:  

Keywords:  DAS181; Human metapneumovirus; attachment; infectivity; sialic acids; sialidase fusion protein

Mesh:

Substances:

Year:  2016        PMID: 27620888      PMCID: PMC5890507          DOI: 10.1177/2040206616665971

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  15 in total

Review 1.  New Approaches for Immunization and Therapy against Human Metapneumovirus.

Authors:  Sherry C Wen; John V Williams
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

2.  Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

Authors:  S A Feldman; R M Hendry; J A Beeler
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans.

Authors:  Isidoro Martínez; José A Melero
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

Review 4.  Epidemiology of human metapneumovirus.

Authors:  Jeffrey S Kahn
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

5.  DAS181 inhibits H5N1 influenza virus infection of human lung tissues.

Authors:  Renee W Y Chan; Michael C W Chan; Adam C N Wong; Rositsa Karamanska; Anne Dell; Stuart M Haslam; Alan D L Sihoe; W H Chui; Gallen Triana-Baltzer; Qixiang Li; J S Malik Peiris; Fang Fang; John M Nicholls
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

6.  A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection.

Authors:  Ronald B Moss; Carrie Hansen; Rebecca L Sanders; Stephen Hawley; Tiejun Li; Roy T Steigbigel
Journal:  J Infect Dis       Date:  2012-10-08       Impact factor: 5.226

7.  DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.

Authors:  Jessica A Belser; Xiuhua Lu; Kristy J Szretter; Xiaoping Jin; Laura M Aschenbrenner; Alice Lee; Stephen Hawley; Do Hyong Kim; Michael P Malakhov; Mang Yu; Fang Fang; Jacqueline M Katz
Journal:  J Infect Dis       Date:  2007-10-31       Impact factor: 5.226

8.  Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry.

Authors:  Rachel M Schowalter; Diana V Pastrana; Christopher B Buck
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

9.  Structures of Merkel cell polyomavirus VP1 complexes define a sialic acid binding site required for infection.

Authors:  Ursula Neu; Holger Hengel; Bärbel S Blaum; Rachel M Schowalter; Dennis Macejak; Michel Gilbert; Warren W Wakarchuk; Akihiro Imamura; Hiromune Ando; Makoto Kiso; Niklas Arnberg; Robert L Garcea; Thomas Peters; Christopher B Buck; Thilo Stehle
Journal:  PLoS Pathog       Date:  2012-07-26       Impact factor: 6.823

Review 10.  Breaking in: human metapneumovirus fusion and entry.

Authors:  Reagan G Cox; John V Williams
Journal:  Viruses       Date:  2013-01-16       Impact factor: 5.048

View more
  3 in total

Review 1.  Influenza antivirals currently in late-phase clinical trial.

Authors:  Paulina Koszalka; Danielle Tilmanis; Aeron C Hurt
Journal:  Influenza Other Respir Viruses       Date:  2017-02-28       Impact factor: 4.380

Review 2.  Current and Novel Approaches in Influenza Management.

Authors:  Erasmus Kotey; Deimante Lukosaityte; Osbourne Quaye; William Ampofo; Gordon Awandare; Munir Iqbal
Journal:  Vaccines (Basel)       Date:  2019-06-18

Review 3.  A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines.

Authors:  Surojit Banerjee; Debadri Banerjee; Anupama Singh; Vikas Anand Saharan
Journal:  AAPS PharmSciTech       Date:  2022-03-21       Impact factor: 4.026

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.